Yawei Zhang

Comment on: Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials

D. Ferry, A. Sashegyi, Yong Lin, 2017, Journal of chemotherapy.

Ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Secondary analysis of efficacy and safety results of 4 dosing regimens in the phase II trial I4T-MC-JVDB.

C. Tournigand, J. Ajani, D. Ferry, 2018 .

GPR176 Is a Biomarker for Predicting Prognosis and Immune Infiltration in Stomach Adenocarcinoma

Bin Wang, Shuming Chen, Jianyong Liu, 2023, Mediators of inflammation.

Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials

J. Shih, M. Kudo, Sang-We Kim, 2018, Journal of global oncology.